07 June 2020
Visiongain has launched a new pharma report Dental Implants Market Report 2020-2030: Forecasts by Type (Titanium Implants, Zirconia Implants), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global dental implants market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz billion by 2020 owing to the growing demand for prosthetics, the growing burden of geriatric population coupled with riding dental diseases.
Dental implants are artificial tooth roots that can be inserted into the jaw, replacing the missing tooth. They fuse with the underlying bone in a process called osseointegration and function as the natural tooth, thereby preserving the jaw structure by preventing bone resorption or atrophy.
Dental implants can be made of materials such as titanium or zirconium and are inserted into the jawbone to supporting tooth prostheses. Implant procedures can be carried out on a single tooth or multiple teeth, depending on the bone quantity available. The availability of Small-Diameter Implants (SDIs) has further simplified the challenge of multiple implants, as they can be carried out even on limited bone volume and in narrow spaces.
The growing concern over oral hygiene and an increasing life expectancy has resulted in higher procedure volumes. An increasingly elderly population is also fueling the demand for dental implants. Growth in surgical procedural volumes increased patient awareness, and technological advances will, in turn, boost the growth of the dental implants market. Several companies are capitalizing on the growth opportunities offered by the dental implants market, both in developed nations such as the US and in emerging markets, by launching products with advanced features.
The growing number of dental injuries is anticipated to boost the market growth for dental implants. As per the Journal of the American Dental Association (JADA), it was reported that 13-39% of all dental injuries are sports-related. Dental implants help replace missing or damaged teeth in cases of dental injuries.
North America dominated the global dental implants market owing to the presence of major players, the presence of well-established dental facilities. Also, the government has launched affordable dental care services for children across the United States. Furthermore, rising awareness, growing initiatives to educate people regarding dental implants is anticipated to augur market growth over the forecast period. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing presence of cancer cases in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the dental implants market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global dental implants market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the dental implants market.
For instance, in July 2018, The INSTITUT STRAUMANN AG acquired a 30% stake in its biomaterials partner Botiss Medical AG (Germany) for an undisclosed sum. The acquisition agreement enables INSTITUT STRAUMANN AG (Germany) in expanding its global distribution network of Botiss Medical AG products and its products. This expansion will benefit the dental implant market.
The comprehensive market report features companies such as Anthogyr SAS, Bicon, LLC, BioHorizons IPH, Inc., Cortex Dental Implants Industries Ltd., DENTIS, DENTIUM Co., Ltd., DENTSPLY Sirona, KYOCERA Medical Corporation, Leader Italia, Neobiotech Inc., Nobel Biocare Services AG., OSSTEM IMPLANT, Sweden & Martina S.p.A., The Straumann Group., T-Plus Implant Tech. Co., Zimmer Biomet Holdings, Inc., among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.